Viking Therapeutics, Inc. (NASDAQ:VKTX) is Quantum Private Wealth LLC's 10th Largest Position

Quantum Private Wealth LLC lifted its holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 9.3% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 84,084 shares of the biotechnology company's stock after purchasing an additional 7,161 shares during the period. Viking Therapeutics comprises approximately 1.8% of Quantum Private Wealth LLC's holdings, making the stock its 10th biggest position. Quantum Private Wealth LLC owned approximately 0.08% of Viking Therapeutics worth $5,323,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Blue Trust Inc. purchased a new stake in Viking Therapeutics in the 3rd quarter worth $26,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Viking Therapeutics in the second quarter valued at $27,000. GAMMA Investing LLC increased its position in Viking Therapeutics by 124.6% in the third quarter. GAMMA Investing LLC now owns 438 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 243 shares during the last quarter. Gilliland Jeter Wealth Management LLC purchased a new stake in Viking Therapeutics during the third quarter valued at $32,000. Finally, Massmutual Trust Co. FSB ADV lifted its position in Viking Therapeutics by 84.3% during the third quarter. Massmutual Trust Co. FSB ADV now owns 553 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 253 shares during the last quarter. 76.03% of the stock is currently owned by institutional investors.

Insider Transactions at Viking Therapeutics

In related news, CFO Greg Zante sold 131,687 shares of Viking Therapeutics stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $76.61, for a total value of $10,088,541.07. Following the completion of the sale, the chief financial officer now directly owns 149,366 shares in the company, valued at $11,442,929.26. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CFO Greg Zante sold 131,687 shares of the business's stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $76.61, for a total value of $10,088,541.07. Following the completion of the transaction, the chief financial officer now owns 149,366 shares of the company's stock, valued at $11,442,929.26. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Sarah Kathryn Rouan sold 11,000 shares of the company's stock in a transaction on Friday, October 25th. The stock was sold at an average price of $80.89, for a total value of $889,790.00. Following the sale, the director now owns 9,500 shares of the company's stock, valued at approximately $768,455. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 525,473 shares of company stock valued at $37,088,158. 4.70% of the stock is currently owned by corporate insiders.

Viking Therapeutics Stock Performance

Viking Therapeutics stock traded down $0.37 during trading hours on Friday, hitting $68.48. The company had a trading volume of 3,878,237 shares, compared to its average volume of 4,505,156. The firm has a market cap of $7.63 billion, a P/E ratio of -73.42 and a beta of 1.00. The company has a 50-day moving average price of $64.68 and a two-hundred day moving average price of $61.85. Viking Therapeutics, Inc. has a 1 year low of $9.34 and a 1 year high of $99.41.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last announced its quarterly earnings results on Wednesday, October 23rd. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.02. During the same period in the previous year, the business posted ($0.23) earnings per share. As a group, equities research analysts anticipate that Viking Therapeutics, Inc. will post -0.98 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on VKTX. StockNews.com upgraded shares of Viking Therapeutics to a "sell" rating in a research report on Tuesday, October 15th. Morgan Stanley reaffirmed an "overweight" rating and issued a $105.00 price objective on shares of Viking Therapeutics in a research note on Thursday, September 12th. Oppenheimer reissued an "outperform" rating and set a $138.00 target price on shares of Viking Therapeutics in a research report on Wednesday, September 25th. HC Wainwright increased their price target on Viking Therapeutics from $90.00 to $102.00 and gave the company a "buy" rating in a report on Monday. Finally, Raymond James lifted their price objective on shares of Viking Therapeutics from $116.00 to $118.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 25th. One analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Viking Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $109.80.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.